DOCSLIB.ORG

A Review and Guide on the Use of Sacubitril/Valsartan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Review and Guide on the Use of Sacubitril/Valsartan Heart Online First, published on May 26, 2016 as 10.1136/heartjnl-2014-306775 Review The neprilysin pathway in heart failure: a review and Heart: first published as 10.1136/heartjnl-2014-306775 on 20 May 2016. Downloaded from guide on the use of sacubitril/valsartan Pardeep S Jhund, John J V McMurray BHF Cardiovascular Research ABSTRACT and the sympathetic nervous system, and the action Centre, Institute of Inhibition of neurohumoural pathways such as the renin of vasopressin, lead to increased ventricular preload Cardiovascular and Medical Sciences, University of angiotensin aldosterone and sympathetic nervous and afterload and elevated wall stress which in turn Glasgow, Glasgow, UK systems is central to the understanding and treatment of lead to production of pre-pro B-type natriuretic heart failure (HF). Conversely, until recently, potentially peptide (BNP) which is cleaved to BNP and Correspondence to beneficial augmentation of neurohumoural systems such N-terminal proBNP (NT-proBNP). The release of Dr Pardeep S Jhund, British as the natriuretic peptides has had limited therapeutic natriuretic peptides may also be determined by the Heart Foundation Cardiovascular Research success. Administration of synthetic natriuretic peptides levels of other neurohormones such as angiotensin 6 Centre, University of Glasgow, has not improved outcomes in acute HF but modulation II and endothelin. The peptide BNP acts to 126 University Place, Glasgow of the natriuretic system through inhibition of the promote natriuresis and vasodilation (NT-proBNP is G12 8TA, UK; pardeep.jhund@ enzyme that degrades natriuretic (and other vasoactive) physiologically inactive). Atrial stretch leads to the glasgow.ac.uk peptides, neprilysin, has proven to be successful. After production of pre-proatrial or A-type natriuretic Received 5 October 2015 initial failures with neprilysin inhibition alone or dual peptide and ultimately atrial natriuretic peptide Accepted 14 April 2016 neprilysin-angiotensin converting enzyme (ACE) (ANP) which has similar biological properties to inhibition, the Prospective comparison of angiotensin BNP.5 Urodilatin (which is structurally related to receptor neprilysin inhibitor (ARNI) with ACEI to ANP), is derived from the same precursor in the Determine Impact on Global Mortality and morbidity in kidneys.7 C-type natriuretic peptide (CNP) is Heart Failure trial (PARADIGM-HF) trial demonstrated released from endothelial cells and acts in a para- that morbidity and mortality can be improved with the crine fashion but is only found in low concentra- angiotensin receptor blocker neprilysin inhibitor tions in circulating blood.5 Two strategies have been sacubitril/valsartan (formerly LCZ696). In comparison to employed to try and improve outcomes in HF-REF the ACE inhibitor enalapril, sacubitril/valsartan reduced via modulation of this pathway. The first is the the occurrence of the primary end point (cardiovascular administration of exogenous natriuretic peptides. death or hospitalisation for HF) by 20% with a 16% Nesiritide, a recombinant human BNP, initially reduction in all-cause mortality. These findings suggest showed promising beneficial effects on haemo- that sacubitril/valsartan should replace an ACE inhibitor dynamics and natriuresis in patients with HF-REF.8 or angiotensin receptor blocker as the foundation of However, in a large-scale randomised controlled http://heart.bmj.com/ treatment of symptomatic patients (NYHA II–IV) with HF trial, nesiritide failed to improve outcomes (though and a reduced ejection fraction. This review will explore it did improve dyspnoea).9 Although carperitide the background to neprilysin inhibition in HF, the results (recombinant ANP) is used as a treatment for acute of the PARADIGM-HF trial and offer guidance on how to HF in Japan, there is no robust evidence supporting use sacubitril/valsartan in clinical practice. this practice.10 The second strategy is to inhibit the breakdown of natriuretic peptides. ANP, BNP, CNP and urodilatin are cleaved and inactivated by a mem- on September 26, 2021 by guest. Protected copyright. The renin angiotensin aldosterone system (RAAS) brane bound endopeptidase, neprilysin (as well as system is at the core of the pathophysiology of insulin degrading enzyme). Neprilysin is found in a heart failure (HF) and its modulation is central to number of tissues but in especially high concentra- altering the disease process in HF with reduced tions in the kidney. Natriuretic peptides are also ejection fraction (HF-REF). Successive randomised cleared via the natriuretic peptide clearance receptor controlled trials have demonstrated that blockade (NPRC and NPRC3). of RAAS improves morbidity and mortality in – patients with HF-REF.1 3 The prognosis of INITIAL NEPRILYSIN INHIBITORS HF-REF has been improved as a consequence, Initial attempts at inhibiting neprilysin using an although it remains poor4 as it remains a complex oral (racecodotril11) and intravenous (candoxatri- syndrome involving a multitude of neurohormonal lat12) formulation were successful in promoting pathways. Therefore, further therapies to improve natriuresis and increasing urinary excretion of ANP. outcomes in these patients are needed. A further neprilysin inhibitor (ecadotril) had similar effects.13 However, a study of chronic use THE NATRIURETIC PEPTIDE SYSTEM of the oral prodrug candoxatril showed that the The natriuretic peptide system counter regulates initial reduction in blood pressure was not sus- the detrimental effects of the upregulation of RAAS tained and therefore development was stopped.14 To cite: Jhund PS, that occurs in HF-REF, inhibits secretion of argin- This might be explained by the finding that neprily- McMurray JJV. Heart 15–17 Published Online First: ine vasopressin and modulates the autonomic sin also breaks down angiotensin II. Therefore [please include Day Month nervous system in ways that are likely to be benefi- inhibiting neprilysin alone, while raising natriuretic Year] doi:10.1136/heartjnl- cial in this syndrome.5 Sodium and water retention peptides levels, also increases angiotensin II levels 2014-306775 and vasoconstriction caused by activation of RAAS (and other substrates for neprilysin such as Jhund PS, McMurray JJV. Heart 2016;0:1–6. doi:10.1136/heartjnl-2014-306775 1 Copyright Article author (or their employer) 2016. Produced by BMJ Publishing Group Ltd (& BCS) under licence. Review endothelin, vasopressin, bradykinin, etc) potentially counteract- angio-oedema was expected to be lower than with omapatri- – Heart: first published as 10.1136/heartjnl-2014-306775 on 20 May 2016. Downloaded from ing the actions of the former peptides. lat.19 21 Given twice daily, sacubitril/valsartan leads to sustained neprilysin and RAAS inhibition over a 24 h period addressing DUAL NEPRILYSIN AND ACE INHIBITION one limitation of the OVERTURE trial in which omapatrilat The solution to the problem of lone neprilysin inhibition was given as a single large dose once daily.22 That approach may appeared to be dual blockade of RAAS and the natriuretic have contributed to the significant early postdose hypotension peptide system (figure 1). As ACE inhibitors are known to seen with omapatrilat but did not provide sustained inhibition improve outcomes it seemed logical to combine an ACE inhibitor of ACE and neprilysin over 24 h. The systemic exposure deliv- with a neprilysin inhibitor. The combined ACE and neprilysin ered by sacubitril/valsartan 97 mg/103 mg (200 mg LCZ696) is inhibitor omapatrilat was studied in a large randomised con- equivalent to 160 mg of valsartan and neprilysin is almost com- – trolled trial against enalapril 10 mg twice daily in the pletely inhibited for up to 12 h.19 21 Omapatrilat Versus Enalapril Randomized Trial of Utility in The Prospective comparison of ARNI with ACEI to Reducing Events (OVERTURE) trial.18 The primary end point, Determine Impact on Global Mortality and morbidity in Heart death from any cause or HF hospitalisations were not reduced by Failure trial (PARADIGM-HF) was conducted to test whether omapatrilat. Although other secondary end points suggested a 97 mg/103 mg twice daily of sacubitril/valsartan was superior to benefit with omapatrilat (death from any cause or cardiovascular enalapril 10 mg twice daily in reducing the primary end point – (CV) hospitalisation was 9% lower in the omapatrilat group) the of CV death or HF hospitalisation.22 24 All randomised patients rate of angio-oedema was much higher in the omapatrilat group. completed a run-in period of 6–8 weeks during which it was Both ACE and neprilysin break down bradykinin and omapatrilat required that the target dose of both drugs was tolerated prior also inhibits aminopeptidase P which also catabolises bradykinin. to randomisation. Each treatment period (enalapril and sacubi- Therefore, unintended excessive potentiation of bradykinin and tril/valsartan) included a washout period to avoid simultaneous resultant high rates of serious angio-oedema led to the discon- neprilysin and ACE inhibition and the potential risk of tinuation of the clinical development of this drug. angio-oedema (patients with a history of angio-oedema were also excluded). The trial was terminated early, on the recom- ANGIOTENSIN RECEPTOR BLOCKER NEPRILYSIN mendation of the Data Monitoring Committee, due to a sus- INHIBITORS tained and highly significant reduction in the risk of the primary Combining an angiotensin receptor blocker (ARB) and a nepri- composite end point (CV death or HF hospitalisation) and in lysin inhibitor
Load more

Recommended publications
  • (Apis Mellifera) ELISABETH P
    J. Insect Ph.vsiol. Vol. 42, No. 9, pp. 823-828, 1996 Pergamon Copyright 0 1996 Elsevier Science Ltd Printed in Great Britain. All rights reserved PII: SOO22-1910(96)00045-5 0022-1910196 $15.00 + 0.00 Effects of Two Proteinase Inhibitors on the Digestive Enzymes and Survival of Honey Bees (Apis mellifera) ELISABETH P. J. BURGESS,*1 LOUISE A. MALONE,* JOHN T. CHRlSTELLERt Received I1 December 1995; revised und accepted 1 March 1996 Two endopeptidase inhibitors, BPTI (bovine pancreatic trypsin inhibitor) and SBTI (Kunitz soybean trypsin inhibitor), were found to significantly reduce the longevity of adult honey bees (&is mellifera L.) fed the inhibitors ad lib in sugar syrup at l.O%, 0.5% or O.l%, but not at 0.01% or 0.001% (w:v). Bees were taken from frames at emergence, kept in cages at 33”C, and provided with a pollen/protein diet, water and syrup. In vivo activity levels of three midgut endopeptidases (trypsin, chymotrypsin and elastase) and the exopeptidase leucine aminopeptidase (LAP) were determined in bees fed either BPTI or SBTI at l.O%, 0.3% or 0.1% (w:v) at two time points: the 8th day after emergence and when 75% of bees had died. LAP activity levels increased significantly in bees fed with either inhibitor at all concen- trations. At day 8, bees fed BPTI at all concentrations had significantly reduced levels of trypsin, chymotrypsin and elastase. At the time of 75% mortality, bees fed BPTI at each concentration had reduced trypsin levels, but only those fed the inhibitor at the highest dose level had reduced chymotrypsin or elastase activity.
    [Show full text]
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • LGM-Pharma-Regulatory-1527671011
    Pipeline Products List Specialty Portfolio Updated Q2 2018 Updated Q2 2018 See below list of newly approved API’s, samples are readily available for your R&D requirements: Inhalation Ophthalmic Transdermal Sublingual Abaloparatide Defibrotide Sodium Liraglutide Rituximab Abciximab Deforolimus Lixisenatide Rivastigmine Aclidinium Bromide Azelastine HCl Agomelatine Alprazolam Abemaciclib Delafloxacin Lumacaftor Rivastigmine Hydrogen Tartrate Beclomethasone Dipropionate Azithromycin Amlodipine Aripiprazole Acalabrutinib Denosumab Matuzumab Rizatriptan Benzoate Budesonide Besifloxacin HCl Apomorphine Eletriptan HBr Aclidinium Bromide Desmopressin Acetate Meloxicam Rocuronium Bromide Adalimumab Difluprednate Memantine Hydrochloride Rolapitant Flunisolide Bimatoprost Clonidine Epinephrine Aflibercept Dinoprost Tromethamine Micafungin Romidepsin Fluticasone Furoate Brimonidine Tartrate Dextromethorphan Ergotamine Tartrate Agomelatine Dolasetron Mesylate Mitomycin C Romosozumab Fluticasone Propionate Bromfenac Sodium Diclofenac Levocetrizine DiHCl Albiglutide Donepezil Hydrochloride Mometasone Furoate Rotigotine Formoterol Fumarate Cyclosporine Donepezil Meclizine Alectinib Dorzolamide Hydrochloride Montelukast Sodium Rucaparib Iloprost Dexamethasone Valerate Estradiol Melatonin Alemtuzumab Doxercalciferol Moxifloxacin Hydrochloride Sacubitril Alirocumab Doxorubicin Hydrochloride Mycophenolate Mofetil Salmeterol Xinafoate Indacaterol Maleate Difluprednate Fingolimod Meloxicam Amphotericin B Dulaglutide Naldemedine Secukinumab Levalbuterol Dorzolamide
    [Show full text]
  • Neprilysin Is Required for Angiotensin-(1-7)
    Page 1 of 39 Diabetes NEPRILYSIN IS REQUIRED FOR ANGIOTENSIN-(1-7)’S ABILITY TO ENHANCE INSULIN SECRETION VIA ITS PROTEOLYTIC ACTIVITY TO GENERATE ANGIOTENSIN-(1-2) Gurkirat S. Brara, Breanne M. Barrowa, Matthew Watsonb, Ryan Griesbachc, Edwina Chounga, Andrew Welchc, Bela Ruzsicskad, Daniel P. Raleighb, Sakeneh Zraikaa,c aVeterans Affairs Puget Sound Health Care System, Seattle, WA 98108, United States bDepartment of Chemistry, Stony Brook University, Stony Brook, NY 11794, United States cDivision of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA 98195, United States dInstitute for Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY 11794, United States Short Title: Angiotensin-(1-7) and insulin secretion Word count: 3997; Figure count: 8 main (plus 3 Online Suppl.); Table count: 1 Online Suppl. Correspondence to: Sakeneh Zraika, PhD 1660 South Columbian Way (151) Seattle, WA, United States Tel: 206-768-5391 / Fax: 206-764-2164 Email: [email protected] 1 Diabetes Publish Ahead of Print, published online May 30, 2017 Diabetes Page 2 of 39 ABSTRACT Recent work has renewed interest in therapies targeting the renin-angiotensin system (RAS) to improve β-cell function in type 2 diabetes. Studies show that generation of angiotensin-(1-7) by angiotensin converting enzyme 2 (ACE2) and its binding to the Mas receptor (MasR) improves glucose homeostasis, partly by enhancing glucose-stimulated insulin secretion (GSIS). Thus, islet ACE2 upregulation is viewed as a desirable therapeutic goal. Here, we show that although endogenous islet ACE2 expression is sparse, its inhibition abrogates angiotensin-(1-7)-mediated GSIS. However, a more widely expressed islet peptidase, neprilysin, degrades angiotensin-(1-7) into several peptides.
    [Show full text]
  • Next Generation Multifunctional Angiotensin Receptor Blockers
    Hypertension Research (2009) 32, 826–834 & 2009 The Japanese Society of Hypertension All rights reserved 0916-9636/09 $32.00 www.nature.com/hr REVIEW Next generation multifunctional angiotensin receptor blockers Theodore W Kurtz1 and Uwe Klein2 Angiotensin receptor blockers (ARBs) are well-tolerated drugs that are known to be useful for inhibiting activity of the renin– angiotensin (RAS) system, treating hypertension and reducing the risk for cardiovascular disease. However, inhibition of the RAS does not control all pathophysiological mechanisms of hypertension or cardiovascular risk and many patients continue to suffer from cardiovascular events and metabolic disturbances despite being treated with an ARB, an angiotensin-converting enzyme inhibitor or both, in addition to other standard therapies for cardiovascular disease. Recently, it has become apparent that bifunctional molecules can be designed that do more than just block AT1 receptors and that can target additional mechanisms of hypertension, cardiovascular disease and diabetes besides just increased activity of the renin–angiotensin system. Specifically, next generation ARBs are becoming available that are intended to not only antagonize AT1 receptors, but also block endothelin receptors, function as nitric oxide donors, inhibit neprilysin activity and increase natriuretic peptide levels, or stimulate the peroxisome proliferator-activated receptor c (PPARc). In this review, we: (1) discuss the potential importance of multifunctional ARBs that can reduce cardiovascular and metabolic
    [Show full text]
  • 2 Total Pharmaceutical Sales
    OECD Health Statistics 2021 Definitions, Sources and Methods Total pharmaceutical sales Total sales of pharmaceutical products on the domestic market, in total and by selected Anatomical Therapeutic Chemical (ATC) classification groups, based on retail prices (which means the final price paid by the customer). The ATC codes below are based on the 2021 version of the ATC Index. All alterations implemented from January 2021 are available on the WHO Collaborating Centre for Drug Statistics Methodology website at http://www.whocc.no/atc/lists_of_new_atc_ddds_and_altera/alterations_in_atc_ddd/. Note: There are at least three possible sources of under-reporting of drug sales in different countries: 1) sales data may only cover those drugs that are reimbursed by public insurance schemes; 2) they may be based on ex-factory or wholesale prices rather than retail prices; and 3) sales data may exclude drug consumption in hospitals. Data for the following countries under-estimate pharmaceutical sales reported in this section because of one of these limitations: Australia, Austria, France, Germany, Greece, Japan, Luxembourg, the Netherlands, the Slovak Republic (before 2016) and Spain. (For further information, see the country-specific information below). Please also note that depending on the allocation of pharmaceutical products with more than one use, differences in reporting of specific drugs may occur across countries, thereby affecting the relative size of specific ATC groups. Data should reflect total sales for each drug category, based on
    [Show full text]
  • View a Copy of This Licence, Visit
    Choi et al. BMC Cardiovascular Disorders (2020) 20:360 https://doi.org/10.1186/s12872-020-01636-5 RESEARCH ARTICLE Open Access Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study Ik Jun Choi1, Sungmin Lim2* , Youngdeok Hwang3, Dongjae Lee1, Won Jik Lee1, Kwan Yong Lee1, Mi-Jeong Kim1 and Doo Soo Jeon1 Abstract Background: Neprilysin has an essential role in regulating fluid balance and vascular resistance, and neprilysin inhibitors have shown beneficial effects in patients with heart failure. However, the potential predictive value of neprilysin levels as a biomarker for cardiovascular risk remains unclear. The aim of this study was to assess the prognostic value of soluble neprilysin (sNEP) levels in patients with ischemic heart disease. Methods: Neprilysin levels were measured in 694 consecutive patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). These patients were classified into two groups according to their serum levels of neprilysin and categorized into the lower neprilysin group (n = 348) and the higher neprilysin group (n = 346). The primary clinical endpoint was all-cause mortality, and the secondary endpoint was a composite of major adverse cardiac events (MACE). Results: The median sNEP level was 76.0 pg/ml. The median sNEP levels were higher in patients with left ventricular ejection fraction (LVEF) ≥40% (77.6 pg/ml, interquartile range 46.6–141.3) than in those with LVEF < 40% (70.0 pg/ml, interquartile range 47.1–100.6; P = 0.032). Among all patients, each clinical outcome and MACE did not differ significantly according to the groups divided into median, tertile, or quartile of sNEP levels during a median follow-up of 28.4 months.
    [Show full text]
  • Stromal CD10 Expression in Breast Cancer Correlates with Tumor Invasion and Cancer Stem Cell Phenotype
    Louhichi et al. BMC Cancer (2018) 18:49 DOI 10.1186/s12885-017-3951-8 RESEARCH ARTICLE Open Access Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype Tahani Louhichi, Hanene Saad, Myriam Ben Dhiab, Sonia Ziadi and Mounir Trimeche* Abstract Background: Previous investigations have indicated that CD10 is associated with biological aggressivity in human cancers, but the use of this marker for diagnosis and prognosis is more complex. The aim of this study was to evaluate the expression of CD10 in breast cancer and its association with the clinicopathological features. In addition, we investigated whether a relationship exists between CD10 expression and cancer stem cells. Methods: CD10 expression was examined by the immunohistochemistry in a series of 133 invasive breast carcinoma cases. Results were correlated to several clinicopathological parameters. Cancer stem cell phenotype was assessed by the immunohistochemical analysis of CD44 and ALDH1. Results: Significant CD10 expression was found in the fusiform stromal cells in 19.5% of the cases and in the neoplastic cells in 7% of the cases. The stromal CD10 positivity was more frequently found in tumors with lymph node metastasis (p = 0.01) and a high histological grade (p = 0.01). However, CD10 expression by the neoplastic cells correlates with a high histological grade (p = 0.03) and the absence of estrogen (p = 0.002) as well as progesterone (p = 0.001) receptor expression. We also found that CD10 expression by the stromal cells, but not by the neoplastic cells, correlates significantly with the expression of cancer stem cell markers (CD44+/ALDH1+) (p = 0.002).
    [Show full text]
  • Treatment Protocol Copyright © 2018 Kostoff Et Al
    Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al PREVENTION AND REVERSAL OF ALZHEIMER'S DISEASE: TREATMENT PROTOCOL by Ronald N. Kostoffa, Alan L. Porterb, Henry. A. Buchtelc (a) Research Affiliate, School of Public Policy, Georgia Institute of Technology, USA (b) Professor Emeritus, School of Public Policy, Georgia Institute of Technology, USA (c) Associate Professor, Department of Psychiatry, University of Michigan, USA KEYWORDS Alzheimer's Disease; Dementia; Text Mining; Literature-Based Discovery; Information Technology; Treatments Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al CITATION TO MONOGRAPH Kostoff RN, Porter AL, Buchtel HA. Prevention and reversal of Alzheimer's disease: treatment protocol. Georgia Institute of Technology. 2018. PDF. https://smartech.gatech.edu/handle/1853/59311 COPYRIGHT AND CREATIVE COMMONS LICENSE COPYRIGHT Copyright © 2018 by Ronald N. Kostoff, Alan L. Porter, Henry A. Buchtel Printed in the United States of America; First Printing, 2018 CREATIVE COMMONS LICENSE This work can be copied and redistributed in any medium or format provided that credit is given to the original author. For more details on the CC BY license, see: http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License<http://creativecommons.org/licenses/by/4.0/>. DISCLAIMERS The views in this monograph are solely those of the authors, and do not represent the views of the Georgia Institute of Technology or the University of Michigan. This monograph is not intended as a substitute for the medical advice of physicians. The reader should regularly consult a physician in matters relating to his/her health and particularly with respect to any symptoms that may require diagnosis or medical attention.
    [Show full text]
  • Angiotensin Receptor Neprilysin Inhibition (ARNI) Following Acute Myocardial Infarction: Primary Results of the PARADISE-MI Trial Marc A
    Angiotensin Receptor Neprilysin Inhibition (ARNI) Following Acute Myocardial Infarction: Primary Results of the PARADISE-MI Trial Marc A. Pfeffer, MD, PhD Distinguished Dzau Professor of Medicine Harvard Medical School Cardiovascular Division, Brigham and Women’s Hospital for the PARADISE-MI Committees, National Leaders and Investigators SAVE AIRE TRACE Radionuclide Clinical and/or Echocardiographic EF ≤ 40% radiographic signs EF ≤ 35% (1992) of HF (1993) (1995) 0.4 All-Cause Mortality 0.35 0.3 0.25 Placebo ACE-I 0.2 0.15 Placebo: 866/2971 (29.1%) Probability of of Probability Event 0.1 ACE-I: 702/2995 (23.4%) 0.05 OR: 0.74 (0.66–0.83) 0 Years 0 1 2 3 4 ACE-I 2995 2250 1617 892 223 Placebo 2971 2184 1521 853 138 Flather MD, et al. Lancet. 2000;355:1575–1581 Mortality in SAVE, TRACE, AIRE, and VALIANT Favors Active Drug Pfeffer,Pfeffer, McMurray, McMurray, Velazquez, Velazquez, et etal. al. N NEngl Engl J MedJ Med2003;3492003;349 2014 40 Enalapril 1117 32 (n=4212) 914 24 LCZ696 (n=4187) Meier Estimate of Meier Estimate 16 - HR = 0.80 (0.73-0.87) Cumulative (%) Rates Cumulative 8 Kaplan P = 0.0000002 Number needed to treat = 21 0 0 180 360 540 720 900 1080 1260 Patients at Risk Days After Randomization LCZ696 4187 3922 3663 3018 2257 1544 896 249 Enalapril 4212 3883 3579 2922 2123 1488 853 236 McMurray, N Engl J Med. 2014 AMI (0.5-7 days with LVEF ≤40% and/or pulmonary congestion) PLUS any risk enhancer Age ≥70 years Atrial fibrillation eGFR <60 LVEF < 30% Diabetes Killip class ≥III Prior MI STEMI without reperfusion Major Exclusions: Prior HF Clinical instability eGFR <30 Sacubitril/Valsartan Ramipril No run-in Target 97/103 mg BID Target 5 mg BID double-blind -controlled N=2830 active N=2831 Event driven: 711 primary endpoints Median follow-up: 23 months Primary Endpoint: CV death, HF hospitalization, outpatient development of HF Jering, Eur J ACC.21 Secondary Endpoint: CV death or first HF hospitalization Heart Fail.
    [Show full text]
  • Combined Neprilysin and Renin–Angiotensin System Inhibition in Heart Failure with Reduced Ejection Fraction: a Meta-Analysis
    European Journal of Heart Failure (2016) doi:10.1002/ejhf.603 Combined neprilysin and renin–angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis Scott D. Solomon1*, Brian Claggett1, John J.V. McMurray2, Adrian F. Hernandez3, and Gregg C. Fonarow4 1Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 2University of Glasgow, Glasgow, UK; 3Duke University, Durham, NC, USA; and 4Ronald Reagan-UCLA Medical Center, Los Angeles, CA, USA Received 1 March 2016; revised 25 May 2016; accepted 3 June 2016 Aims The combined neprilysin/renin–angiotensin system (RAS) inhibitor sacubitril/valsartan reduced cardiovascular death or heart failure hospitalization, cardiovascular death, and all-cause mortality in a large outcomes trial. While sacubitril/valsartan is the only currently available drug in its class, there are two prior clinical trials in heart failure with omapatrilat, another combined neprilysin/RAS inhibitor. Using all available evidence can inform clinicians and policy-makers. ..................................................................................................................................................................... Methods We performed a meta-analysis using data from three trials in heart failure with reduced EF that compared combined and results neprilysin/RAS inhibition with RAS inhibition alone and reported clinical outcomes: IMPRESS (n = 573), OVERTURE (n = 5770), and PARADIGM-HF (n = 8399). We assessed the pooled hazard ratio (HR) for all-cause death or heart failure hospitalization, and for all-cause mortality in random-effects models, comparing combined neprilysin/RAS inhibition with ACE inhibition alone. The composite outcome of death or heart failure hospitalization was reduced numerically in patients receiving combined neprilysin/RAS inhibition in all three trials, with a pooled HR of 0.86, 95% confidence interval (CI) 0.76–0.97, P = 0.013.
    [Show full text]
  • Metabolic Actions of Natriuretic Peptides and Therapeutic Potential in the Metabolic Syndrome
    Pharmacology & Therapeutics 144 (2014) 12–27 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: G. Eisenhofer Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome Nina Schlueter a,AnitadeSterkea, Diana M. Willmes a, Joachim Spranger a, Jens Jordan b,AndreasL.Birkenfelda,⁎ a Department of Endocrinology, Diabetes and Nutrition, Center for Cardiovascular Research, Charité, University School of Medicine, Berlin, Germany b Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany article info abstract Available online 27 April 2014 Natriuretic peptides (NPs) are a group of peptide-hormones mainly secreted from the heart, signaling via c-GMP coupled receptors. NP are well known for their renal and cardiovascular actions, reducing arterial blood pressure Keywords: as well as sodium reabsorption. Novel physiological functions have been discovered in recent years, including Natriuretic peptides activation of lipolysis, lipid oxidation, and mitochondrial respiration. Together, these responses promote white ANP adipose tissue browning, increase muscular oxidative capacity, particularly during physical exercise, and protect BNP against diet-induced obesity and insulin resistance. Exaggerated NP release is a common finding in congestive Insulin resistance heart failure. In contrast, NP deficiency is observed in obesity and in type-2 diabetes, pointing to an involvement Diabetes fi Obesity of NP in the pathophysiology of metabolic disease. Based upon these ndings, the NP system holds the potential to be amenable to therapeutical intervention against pandemic diseases such as obesity, insulin resistance, and arterial hypertension. Various therapeutic approaches are currently under development. This paper reviews the current knowledge on the metabolic effects of the NP system and discusses potential therapeutic applications.
    [Show full text]